HRT Financial’s GT Biopharma GTBP Stock Holding History

HRT Financial’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,767	Closed	-$9K	–	4155
2025 Q4	$9K	Buy	+11,767	New	+$8.36K	﹤0.01%	3046
2024 Q1	–	Sell	-1,126	Closed	-$8K	–	2608
2023 Q4	$8K	Buy	+1,126	New	+$8.23K	﹤0.01%	2096

Other funds holding GTBP

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

HRT Financial's GTBP Position: Q1 2026 in Review

HRT Financial sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 11,767 shares — an estimated $9K sold.

HRT Financial first reported a position in GTBP in Q4 2023 and held it in 2 quarters. The position peaked at $9K in Q4 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

HRT Financial reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 11,767 GT Biopharma shares in Q1 2026, an estimated $9K.
HRT Financial first reported a position in GT Biopharma in Q4 2023 and held it in 2 quarters.
HRT Financial's GT Biopharma position peaked at $9K in Q4 2025.
42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.